AbbVie Inc. (ABBV)
| Market Cap | 305.03B |
| Revenue (ttm) | 55.53B |
| Net Income (ttm) | 5.08B |
| Shares Out | 1.77B |
| EPS (ttm) | 2.87 |
| PE Ratio | 60.14 |
| Forward PE | 14.60 |
| Dividend | $6.56 (3.80%) |
| Ex-Dividend Date | Jan 15, 2025 |
| Volume | 7,533,214 |
| Open | 172.16 |
| Previous Close | 171.56 |
| Day's Range | 171.22 - 175.66 |
| 52-Week Range | 153.58 - 207.32 |
| Beta | 0.57 |
| Analysts | Strong Buy |
| Price Target | 207.25 (+20.07%) |
| Earnings Date | Jan 31, 2025 |
About ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; E... [Read more]
Financial Performance
In 2023, AbbVie's revenue was $54.32 billion, a decrease of -6.44% compared to the previous year's $58.05 billion. Earnings were $4.82 billion, a decrease of -59.09%.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for ABBV stock is "Strong Buy." The 12-month stock price forecast is $207.25, which is an increase of 20.07% from the latest price.
News
Top 4 Immunology Stocks Poised For Growth In 2025
This article will reveal an in-depth analysis of drugs being developed to combat immunological disorders. Big Pharma is keenly interested in the global immunology drugs market, which is anticipated to...
Income & Growth: 3 Of The Best Dividend Stocks For Any Market
Inflation continues to erode purchasing power, and recent volatility highlights the uncertainty in inflation trends. Despite this, long-term investors can still find opportunities. In an unpredictable...
AbbVie Inc. (ABBV) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)
AbbVie Inc. (NYSE:ABBV) J.P. Morgan 43rd Annual Healthcare Conference January 15, 2025 11:15 AM ET Company Participants Rob Michael - Chief Executive Officer Scott Reents - Executive Vice President, ...
AbbVie to 'commit less capital' towards psychiatric drugs, CEO says
AbbVie will commit less capital towards experimental medicines for psychiatric disease, CEO Robert Michael said at an industry conference on Wednesday.
My Dividend Stock Portfolio: $10,000 In Dividends In 2024 - 97 Holdings With 13 Buys
In December, I invested around $1,200 primarily in Business Development Companies, boosting my annual dividend income by $131 with a full-year total of almost $1,700.
Alzamend Neuro to Present at the Sequire Investor Summit
ATLANTA--(BUSINESS WIRE)---- $ABBV #ALZN--Alzamend Neuro to Present at Sequire Investor Summit; Company to Report Progress with Clinical Trials to be Initiated in 2025 and Expected Milestones.
AbbVie Has Immense Cash Flow Potential
AbbVie, with a market cap of over $300 billion, shows strong cash flow potential despite patent expirations, making it a valuable investment. The company reported strong 3Q financials, with adjusted d...
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...
Drugmakers rush to sign deals on first day of industry conference
Drugmakers signed deals worth at least $18 billion in combined value on Monday, the first day of the healthcare industry's top conference in San Francisco.
China's Simcere Pharma grants AbbVie option to license its blood cancer drug candidate
Simcere Pharmaceutical said on Monday its unit had granted U.S. drugmaker AbbVie the option to license its new blood cancer drug candidate outside China.
Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
SHANGHAI and NORTH CHICAGO, Ill. , Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an option t...
AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
NORTH CHICAGO, Ill. and SHANGHAI , Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to lic...
AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
Pivotal data evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet age-related macular degeneration (wet AMD) are expected in 2026 AbbVie and REGENXBIO wil...
11 Upcoming Dividend Increases, Including A Dividend King
Hormel Foods extends its 52-year dividend streak with a 2.6% increase; the group averages a 5.9% increase, median 5.8%. My strategy focuses on buying, holding, and adding to companies with consistent ...
AbbVie Takes $3.5B Impairment Charge for Failed Schizophrenia Drug
AbbVie (ABBV) shares fell Friday after the biotech firm announced it would take an estimated $3.5 billion impairment charge because of the failure of one of its drugs.
MoneyShow's Best Investment Ideas For 2025: Part 2
MoneyShow presents top investment ideas for 2025 from their contributors. This year's edition presents a broad mix of theme-based stock picks, momentum-driven high-flyers and beaten-up stocks with tur...
Abbvie to record $3.5 bln charge related to schizophrenia drug
Abbvie said on Friday it will record a charge of about $3.5 billion related to its experimental schizophrenia drug, emraclidine, which recently failed in two mid-stage studies.
AbbVie to Present at the 43rd Annual J.P. Morgan Healthcare Conference
NORTH CHICAGO, Ill. , Jan. 9, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present at the 43rd Annual J.P.
CoolMonth is Back With Deals on CoolSculpting® Elite by Allergan Aesthetics
Get Treated with CoolSculpting® Elite and Enter for a Chance to Win $10,000* Starting Today, First-Time Users Can Claim $300 Off Their Treatment† IRVINE, Calif. , Jan. 7, 2025 /PRNewswire/ -- Allergan...
AbbVie cuts 2024 profit forecast on acquisition expenses
AbbVie lowered its 2024 adjusted profit forecast on Monday as the drugmaker incurred $1.6 billion in acquisition expenses related to milestone payments as well as research-and-development costs.
AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call
NORTH CHICAGO, Ill. , Jan. 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2024 financial results on Friday, January 31, 2025, before the market opens.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Highest Quality Dividend Kings For 2025
Only 11 Dividend Kings outperformed the S&P 500 during the last decade based on Total Return. 5 Dividend Kings earn the rank of "High Quality" based on my custom quantitative model. Using a variation ...
Into 2025: Top 8 Stocks I Own And Why (Part II)
2024 is going out with a bang as mystery drones, Federal Reserve hawkishness, and quantum stocks dominate headlines. It's time to look towards 2025 after another banner year for stocks. Here are four ...